Contact Us

Press Releases 2023

Biocon Biologics / Press Releases / Press Releases 2023

Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars’ Business In North America, Ahead of Schedule

Wed, 06-Sep-2023
Posted by: Biocon Biologics

Biocon Q1FY24 Revenue at Rs 3,516 Cr, Up 59%; Biosimilars Up 106%; Research Services Up 25%

Thu, 10-Aug-2023
Posted by: Biocon Biologics

Biocon Biologics Announces Key Leadership Appointments

Fri, 04-Aug-2023
Posted by: Biocon Biologics

Biocon Biologics Announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept

Mon, 24-Jul-2023
Posted by: Biocon Biologics

Biocon Biologics Expands Footprint in Emerging Markets Takes Over the Commercialization of Biosimilars Business from Viatris in 70+ countries

Wed, 05-Jul-2023
Posted by: Biocon Biologics

After Five Years of Successful Experience Internationally, Biocon Biologics’ Hulio® Biosimilar to Humira®, Now Available in the United States

Hulio bAdalimumab

Mon, 03-Jul-2023
Posted by: Biocon Biologics

Biocon Group concluded the month-long sustainability initiatives commemorating ‘World Environment Day’ initiated with ‘Nature Positive’ Campaign

Fri, 30-Jun-2023
Posted by: Biocon Biologics

Biocon Q4FY23 Revenue at Rs 3,929 Cr, Up 59%; Biosimilars Up 114%; Research Services Up 31%

Tue, 23-May-2023
Posted by: Biocon Biologics

Serum & Biocon Biologics Agree to Restructure Equity Investment

Tue, 25-Apr-2023
Posted by: Biocon Biologics

Biocon Awarded a Silver Medal by EcoVadis for its Sustainability Accomplishments

Mon, 03-Apr-2023
Posted by: Biocon Biologics

1
2
3